Kevin Rinker

Debevoise & Plimpton LLP 

Kevin Rinker is Co-Chair of the firm’s Mergers & Acquisitions Group and a leader in the Private Equity and Healthcare Groups. Mr. Rinker has a broad-based transactional practice with extensive experience advising multi-national corporations and private equity firms in structuring and negotiating mergers, acquisitions, investments, divestitures, licensing arrangements and other corporate transactions.

He has handled matters across many industries, with experience in the technology, media and business services sectors, in addition to healthcare. Mr. Rinker has represented a number of leading corporate and private equity clients, including Clayton, Dubilier & Rice, Morgan Stanley Private Equity, Johnson & Johnson, Providence Equity Partners, Nestlé S.A., The Carlyle Group, General Electric, Cerberus Capital Management, Hospital Corporation of America, and Envision Healthcare.

Mr. Rinker is ranked as a leading M&A and private equity buyouts lawyer by Chambers Global(2019) and Chambers USA (2018), where he is described as “very smart, creative and thorough,” with “a strong ability to identify the most material issues and succinctly articulate how to address them or how to think through downside scenarios.” Recognized by clients for his “commercial mind set” and “ability to understand, develop and present unique solutions,” clients reveal that he is “able to anticipate issues across a number of fronts,” and that his negotiation skills make a significant difference in a transaction.

He is also recommended for private equity buyouts and M&A by The Legal 500 US (2018), with previous editions of the guide describing him as “very accessible and commercial,” “a strong negotiator,” “extremely client oriented” and “calm under fire.” Clients say he has the “experience base, familiarity with market precedents and ability to help create unique structures to position clients to make the best deals they can.” Mr. Rinker is also ranked as a leading lawyer by IFLR1000 (2019).

He was selected by the New York Times as a member of the next generation of leading deal makers, and was included in its “Facebook of Wall Street’s Future.” Mr. Rinker was twice named a “Law360 MVP” (2013, 2016) for his exceptional work in private equity. In addition, Mr. Rinker led the firm’s representation of Access Industries, as part of a consortium with Apollo Global Management and Riverstone Holdings, in its $7.15 billion acquisition of the oil and gas exploration and production assets of El Paso, which was named “Private Equity Deal of the Year” by International Financial Law Review.

Mr. Rinker is a frequent author and speaker on topics relating to mergers and acquisitions. He is a contributing author of the Debevoise & Plimpton Private Equity Report and is the co-editor of, and contributor to, the Health Care Mergers and Acquisitions Answer Book (Practising Law Institute, 2018), an extensive reference guide addressing structuring, regulatory, due diligence and documentation issues in healthcare M&A and licensing transactions. His articles include “A Look at Recent Efforts to Contain Health Care Costs,” Law360 (January, 2018); “How Section 1332 Waivers Could Impact Health Care Reform,” Law360 (July, 2017); “Shining a Light on GOP Plan for Health Care Reform,” Law360 (March, 2017); “The Outlook For The Pharmaceutical Industry Under Trump,” Law360 (January, 2017); “The Outlook on Drug Pricing: At What Cost?,” Law360(December, 2016) and “Lot of Inversion Talk, But Do You Know the Basics?,” Law360 (August 2014); “MAC Clauses in the UK and US: Much Ado About Nothing?,”The M&A Lawyer (March, 2014); “Imitation is the Sincerest Form of Flattery: Continued Use of Private Equity Technology in Acquisitions by Strategic Buyers,” The M&A Lawyer (January, 2013); “Allocating Financing Risk: Recent Trends in Sponsor-Led Public Company LBOs,” The M&A Lawyer (February, 2011); “Something Old, New, Borrowed and Blue,” The Deal (August, 2009); and “Bridging the Gap,” The Deal (May, 2009).

Mr. Rinker joined Debevoise in 2000 and became a partner in 2007. He received his B.A. in 1994 from Tufts University and his J.D. in 1999 from the Georgetown University Law Center, where he was on the editorial board of The Tax Lawyer and served as a Teaching Fellow in the LL.M. program. Mr. Rinker is a member of the Board of Directors of Partnership with Children, a non-profit organization that assists at-risk youths in the New York City area.


  • Healthcare
    • HCA Healthcare in its $1.5 billion acquisition of Mission Health, a nonprofit North Carolina health system.
    • Envision Healthcare in its $15 billion merger with AMSURG, creating one of the largest U.S. providers of specialty physicians and hospital-related services.
    • Johnson & Johnson in its acquisition of Zarbee’s Naturals, a leader in naturally-based healthcare products.
    • The Carlyle Group in its acquisition of MedRisk, a provider of managed physical medicine to the workers’ compensation industry.
    • Johnson & Johnson in its global co-development and commercialization agreement with Theravance Biopharma, relating to various compounds being developed for the treatment of inflammatory bowel disease, including Crohn’s and ulcerative colitis.
    • NJRetina in the formation of a strategic affiliation with NJEye and Quad-C Management.
    • Clayton, Dubilier & Rice in the acquisition of Carestream Dental, the digital dental business of Carestream Health.
    • Johnson & Johnson in its $330 million acquisition from AstraZeneca of the global rights outside of the U.S. to Rhinocort Aqua, a line of nasal sprays used to treat allergies.
    • Galderma Pharma in various licensing and development arrangements, including its agreement with NovaBay Pharmaceuticals to develop and commercialize NovaBay’s novel Aganocide drugs for major dermatological conditions, and its agreement with ZARS Pharma relating to the worldwide promotion and distribution of a topical anesthetic cream, Pliaglis.
    • Nestlé in its $1.4 billion acquisition of the aesthetic dermatology business of Valeant Pharmaceuticals.
    • Morgan Stanley Investment Management in its acquisition of Manna Pro, a leading producer of nutritional supplements and other animal products, from The Carlyle Group.
    • Johnson & Johnson in its purchase of an exclusive option to acquire Bird Rock Bio, a clinical stage biopharmaceutical company focused on innovative immuno-inflammatory regulators that can be used in the treatment of liver disease.
    • PharMEDium, a Clayton, Dubilier & Rice portfolio company and the leading national provider of outsourced compounded sterile preparations to acute care hospitals in the United States, in its $2.6 billion sale to AmerisourceBergen.
    • AssuraMed in its $2 billion sale to Cardinal Health.
    • Johnson & Johnson in the sale to SK Capital Partners of its global narcotics business, one of the world’s leading producers of opiates.
    • Envision Healthcare in its $620 million acquisition of Rural/Metro Corporation.
    • Clayton, Dubilier & Rice in its acquisition of a controlling stake in Drive DeVilbiss Healthcare, a global manufacturer of medical products.
    • Nestlé Skin Health in its $1 billion acquisition of Guthy Renker’s worldwide Proactiv business, the world’s leading non-prescription acne brand.
    • Johnson & Johnson in the sale of its worldwide intimate health business to Reckitt Benckiser, a UK-based consumer goods company.
    • PharMEDium, a Clayton, Dubilier & Rice portfolio company and the leading national provider of outsourced compounded sterile preparations to acute care hospitals in the United States, in its $2.6 billion sale to AmerisourceBergen.
    • Galderma Pharma in its agreement with Valeant Pharmaceuticals to restructure certain North American licensing arrangements in connection with Valeant’s $2.6 billion acquisition of Galderma’s long-time partner Medicis Pharmaceutical.
    • Hisamitsu Pharmaceutical, a leading transdermal patch manufacturer listed on the Tokyo stock exchange, in its $428 million acquisition of Nasdaq-listed Noven Pharmaceuticals via an all-cash tender offer.
  • Technology, Media & Telecommunications
    • Warner Music Group in its $765 million acquisition of Parlophone Label Group from Universal Music Group.
    • Providence Equity Partners in its acquisition from General Motors and Ford of a majority stake in OEConnection, the established market leader in cloud-based technology solutions that facilitate the efficient location, sale, distribution and dynamic pricing of automotive parts.
    • Dell in its proposed, and later terminated, $1.5 billion acquisition of 3PAR, a global data-storage provider.
    • General Electric in the repurchase of Vivendi’s stock of NBC Universal for $5.8 billion along with advice to NBC Universal on certain corporate matters related to the formation of the NBC Universal – Comcast joint venture valued at $37.5 billion.
    • The Dolan family in its $22 billion effort to take Cablevision private.
    • LivingSocial in its acquisition of Ticket Monster, the leading social commerce website in South Korea.
    • Viewdle, a facial recognition technology provider, in its sale to Motorola Mobility, a division of Google.
    • General Electric and NBC in their acquisition of Vivendi Universal Entertainment and formation of NBC Universal, a $43 billion broadcast, cable, studio, film and diversified entertainment company owned 20% by Vivendi and 80% by General Electric.
    • NBC Universal in its $3.4 billion purchase of common and preferred interests of Vivendi Universal Entertainment LLP from IAC/InterActiveCorp., resulting in VUE being wholly owned by NBC.
    • Providence Equity Partners and Altegrity in the $520 million sale of Explore Information Services, a provider of database insurance technologies and e-government applications, to NYSE-listed Solera Holdings.
  • Business Services
    • Morgan Stanley Private Equity in the $600 million sale of Creative Circle, a leading professional staffing firm specializing in advertising, creative and marketing talent, to NYSE-listed On Assignment for a mix of stock and cash consideration.
    • Morgan Stanley Private Equity in its acquisition of CoAdvantage, a leading Professional Employer Organization.
    • Morgan Stanley Private Equity in its $410 million sale of EmployBridge, a leading provider of outsourced human resource and temporary staffing services, to Select Staffing, an Anchorage Capital backed competitor.
    • Altegrity, a global, diversified risk and information services company, together with its operating businesses Kroll, HireRight and USIS, in their pre-negotiated Chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware, in which they successfully restructured more than $1.8 billion in funded indebtedness.
    • Morgan Stanley Private Equity in its acquisition of Creative Circle, one of North America’s largest independent staffing firms specializing in advertising, creative and marketing talent.
    • Morgan Stanley Private Equity in its acquisition of EmployBridge, a provider of outsourced human resource and specialty-branded temporary staffing services.
      Altegrity and Providence Equity Partners in their $1.13 billion acquisition of Kroll from Marsh & McLennan.
    • Providence Equity Partners in its $1.5 billion acquisition of US Investigations Services, a leading provider of information, security and risk management services.
  • Energy
    • Access Industries, as part of a consortium with Apollo Global Management and Riverstone Holdings, in its $7.2 billion acquisition of the oil and gas exploration and production assets of El Paso.
    • Clayton, Dubilier & Rice and Brand Energy and Infrastructure Services in the merger of Brand Energy and Safway Group, forming the leading global industrial service business with over $5 billion in revenue.
    • Brand Energy & Infrastructure Services in its buyout of Harsco Corporation’s 26% interest in Brand, a leading single-source provider of specialized industrial services to the worldwide energy and infrastructure sectors.
    • Clayton, Dubilier & Rice in its acquisition of up to a 49% stake in NYSE-listed CHC Group, the world’s largest commercial helicopter operator with an enterprise value of $1.9 billion.
  • Industrials
    • Clayton, Dubilier & Rice in its $2.5 billion acquisition of HD Supply’s Waterworks Division, the largest distributor of waterworks products in the U.S.
    • Cerberus Capital Management in its acquisition of Electrical Components International, the world’s leading manufacturer of wire harnesses, control boxes and value-added assembly services, from KPS Capital Partners.
    • Cerberus Capital Management in its acquisition of Cyanco International, the largest global producer of sodium cyanide.
  • Financial Services
    • Cornell Capital as a leading investor in the $2.05 billion acquisition of Talcott Resolution, The Hartford’s run-off life and annuity businesses.
    • Morgan Stanley Private Equity in its acquisition of Access Cash, a Canadian independent service organization that manages the country’s second largest network of automated teller machines.


  • Georgetown University Law Center, 1999, J.D.
  • Tufts University, 1994, B.A.

Bar Admissions:

  • New York


Rate : $$$

What types of cases Attorney Kevin Rinker & Debevoise & Plimpton LLP  can handle?
Debevoise & Plimpton LLP  can handle cases related to laws concerning Health Care, Mergers & Acquisitions. We manually verify each attorney’s practice areas before approving their profiles and reviews on our website.
Where is Debevoise & Plimpton LLP  located?
Debevoise & Plimpton LLP  is located at 919 Third Avenue, New York, NY 10022, USA. You can reach out to Debevoise & Plimpton LLP  using their phone line 212 909 6569. You can also check their website or email them at [email protected].
How much would it cost to hire Debevoise & Plimpton LLP ?
Kevin Rinker lawyer charges are specific to each case. However, they work with contingency fees and its ranges from $$ to $$$. They also provide free consultation [and no obligation quotes] if you are interested to hire.
Are Kevin Rinker reviews trust-able?
We have the ratings and reviews moderation team who checks and verifies every review submitted on our website manually. You can trust all the reviews you see on Kevin Rinker lawyer profile listing.

1 review

  1. Negative


    Complete disaster and disorganized. Hard to get a hold of. Would not recommend.

Rate and write a review

Your email address will not be published. Required fields are marked *

Is this your profile?Claim it now.

Make sure your information is up to date.
Debevoise & Plimpton LLP 
New York 10022 NY US
Get directions

Brian Orlow

Main Street 71-18
11367 NY US

Lina Stillman

Broadway 42
New York 10006 NY US